k-nk002
Cell therapyexperimental
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04395092)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04395092 | Phase 2 | Jul 31, 2020 | Blood and Marrow Transplant Clinical Trials Network, Kiadis Pharma, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Ohio State University, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blood and Marrow Transplant Clinical Trials Network | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Kiadis Pharma | For profit | 1 | 1 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2020 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2020 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1